Recombinetics (United States)
Recombinetics is a St. Paul, Minnesota-based bio-engineering company. The company was founded in 2008, and has since raised $31 million from private investors. Mark Platt is the CEO. In November 2024, Recombinetics filed for Chapter 11 bankruptcy protection. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Recombinetics (United States), United States, covering academic research published from 2005 to 2024. Read More.
Open Access Percentage
70%
Total
Publications
182
Total Open
Publications
127
Total
Citations
7K
Open Access
Percentage
70%
Total
Publications
182
Total Open
Publications
127
Total
Citations
7K
Breakdown
Publisher Open
16%
Both
41%
Other Platform Open
13%
Closed
30%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 56%
57
Hybrid 16%
16
No Guarantees 28%
29
Other Platform Open
Domain 78%
76
Institution 32%
31
Other Internet 26%
25
Preprint 11%
11
Public 2%
2
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 75 |
DOI | Other Internet | 21 |
Europe PMC | Domain | 12 |
bioRxiv | Preprint | 11 |
Unknown Repository | Other Internet | 9 |
Universidade Estadual Paulista (Unesp) | Institution | 8 |
University of Edinburgh | Institution | 6 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 4 |
Istituto di Ematologia di Bologna | Institution | 4 |
epfl.ch OAI-PMH Repository | Institution | 4 |